Envoy Medical (COCH) Non-Current Deffered Revenue (2021 - 2023)

Envoy Medical has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $10.4 million for Q2 2023.

• Non-Current Deffered Revenue for Q2 2023 came in at $10.4 million, down 30.0% year-over-year; the trailing twelve-month figure through Jun 2023 was $10.4 million (down 30.0% YoY), and the FY2022 annual result was $10.4 million, down 30.0% from the prior year.
• Non-Current Deffered Revenue came in at $10.4 million for Q2 2023 at Envoy Medical, roughly flat from $10.4 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $14.9 million in Q2 2021 to a low of $10.4 million in Q3 2022.
• The 3-year median for Non-Current Deffered Revenue is $14.8 million (2021), against an average of $13.1 million.
• Peak annual rise in Non-Current Deffered Revenue reached 1.19% in 2022, while the deepest fall reached 30.0% in 2022.
• Envoy Medical's Non-Current Deffered Revenue stood at $14.9 million in 2021, then dropped by 30.0% to $10.4 million in 2022, then changed by 0.0% to $10.4 million in 2023.
• The last three Non-Current Deffered Revenue figures came in at $10.4 million (Q2 2023), $10.4 million (Q1 2023), and $10.4 million (Q4 2022), per Business Quant data.